脓毒症宿主反应靶向治疗:当前方法与未来证据
脓毒症是感染引起宿主反应失调并导致器官衰竭,是全球主要死因之一。免疫反应失衡在其病理生理中起重要作用,患者可同时或相继出现全身或局部过度炎症和免疫抑制。尽管有多种有效免疫调节治疗可用,但抑制或刺激免疫系统在脓毒症中的尝试迄今未能改善患者结局。原因可能多方面,包括未能识别特定免疫干预的应答者,以及器官功能障碍的复杂病理生理不仅由免疫病理引起,还涉及凝血系统、实质器官和内皮功能障碍。越来越多证据提示,对异质性脓毒症人群按宿主反应分层可能带来更有效的治疗;本综述旨在概述优化宿主反应多方面的当前研究,并讨论脓毒症精准医学方法的未来前景。
要点
- 脓毒症免疫调节治疗迄今未能改善结局,可能因未识别特定干预的应答者。
- 患者可同时或相继出现全身或局部过度炎症和免疫抑制状态。
- 器官功能障碍不仅由免疫病理引起,还涉及凝血系统、实质器官和内皮功能障碍。
- 越来越多证据提示,按宿主反应对脓毒症患者分层可能带来更有效的治疗。
适用人群与场景
- 脓毒症患者,即感染引起宿主反应失调并导致器官衰竭者。
研究设计与关键结果
- 本综述概述优化宿主反应多方面的当前研究,并讨论脓毒症精准医学方法的未来前景。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 越来越多证据提示,按宿主反应对异质性脓毒症人群分层可能带来更有效的治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis, a dysregulated host response to infection characterized by organ failure, is one of the leading causes of death worldwide. Disbalances of the immune response play an important role in its pathophysiology. Patients may develop simultaneously or concomitantly states of systemic or local hyperinflammation and immunosuppression. Although a variety of effective immunomodulatory treatments are generally available, attempts to inhibit or stimulate the immune system in sepsis have failed so far to improve patients' outcome. The underlying reason is likely multifaceted including failure to identify responders to a specific immune intervention and the complex pathophysiology of organ dysfunction that is not exclusively caused by immunopathology but also includes dysfunction of the coagulation system, parenchymal organs, and the endothelium. Increasing evidence suggests that stratification of the heterogeneous population of septic patients with consideration of their host response might led to treatments that are more effective. The purpose of this review is to provide an overview of current studies aimed at optimizing the many facets of host response and to discuss future perspectives for precision medicine approaches in sepsis.
参考来源
- Bode C, Weis S, Sauer A, et al. Targeting the host response in sepsis: current approaches and future evidence. Crit Care. 2023. PMID: 38057824. doi:10.1186/s13054-023-04762-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。